225Ac-TR2205

N/A

Report date: 2026/03/26 20:00:17

NME

Base Information

Drug Name225Ac-TR2205

Drug Alias Name225Ac-TR2205

ClassificationSmall molecules > Heterocyclic drugsDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Radioactive diagnostic agent +[5]

Mechanisms of ActionProstate-Specific Membrane Antigen binders

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesCancer Hospital of Shandong First Medical University

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCancer Hospital of Shandong First Medical University

Inactive CompaniesN/A

Active IndicationsTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A